Real-World Experience Using Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis From a Single Outpatient Dermatology Clinic

被引：3
|
作者：
Cirone, Katrina D. [1 ]
Lovegrove, Fiona E. [1 ,2 ,3 ]
机构：
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Lovegrove Dermatol, London, ON, Canada
[3] Lovegrove Dermatol, 207-140 Oxford St East, London, ON, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2024年 / 28卷 / 01期
关键词：
bimekizumab; psoriasis; biological therapy; real-world data; systemic therapy; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY;
D O I：
10.1177/12034754231217205
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [31] Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
    Bhatia, Neal
    Vasquez, J. Gabriel
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB72 - AB72
  • [32] Should we customize the treatment with interleukin-17A inhibitors for moderate-to-severe psoriasis in the real-world setting?
    Hu, Kun
    Zhang, Mi
    Yang, Jing
    Wang, Qiaolin
    Tan, Minjia
    Deng, Sichun
    Chen, Junchen
    Zhu, Wu
    Chen, Wendong
    Kuang, Yehong
    Chen, Xiang
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (02) : E262 - E263
  • [33] Real-world dermatology visit in moderate to severe plaque psoriasis patients treated with biologics or apremilast
    Wu, Jashin J.
    Zhang, Jingchuan
    Zhao, Yang
    Martinez, Diane
    Lopez-Gonzalez, Lorena
    Marchlewicz, Elizabeth H.
    Shrady, George
    Mendelsohn, Alan
    Feldman, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB80 - AB80
  • [34] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
    Vasquez, J. Gabriel
    Bhatia, Neal
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [35] Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
    Xiao, Y.
    Lakatos, P. L.
    Bourdages, R.
    Bitton, A.
    Afif, W.
    Kohen, R.
    Berberi, M.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S445 - S445
  • [36] Real-World Experience of Secukinumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis in Greece: 3-Year Interim Results of the SERENA Study
    Ioannides, Dimitrios
    Rigopoulos, Dimitrios
    Papakonstantis, Markos
    Chasapi, Vasiliki
    Deligiannis, Panagiotis
    Rigatos, Panagiotis
    Lefaki, Ioanna
    Papadavid, Evangelia
    Pokas, Eteoklis
    Tsilifis, Spyridon
    Roussaki-Schulze, Angeliki-Viktoria
    Barkis, Ioannis
    Lazaridou, Elisabeth
    Fotiadou, Christina
    Zisimou, Chrysa
    Kallidis, Panagiotis
    Chatzakis, Vasileios
    Oikonomou, Chrysa
    Madia, Xenia
    DERMATOLOGIC THERAPY, 2024, 2024
  • [37] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Spyridon Gkalpakiotis
    Petra Cetkovska
    Petr Arenberger
    Tomas Dolezal
    Monika Arenbergerova
    Barbora Velackova
    Jorga Fialova
    Martina Kojanova
    Dermatology and Therapy, 2021, 11 : 1345 - 1355
  • [38] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Gkalpakiotis, Spyridon
    Cetkovska, Petra
    Arenberger, Petr
    Dolezal, Tomas
    Arenbergerova, Monika
    Velackova, Barbora
    Fialova, Jorga
    Kojanova, Martina
    DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1345 - 1355
  • [39] Upadacitinib for the treatment of moderate-to-severe atopic dermatitis in real-world clinical practice
    Tran, Vanessa
    Ross, Gayle
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 11 - 11
  • [40] Characteristics and treatment pattern comparisons of a real-world cohort of patients eligible and ineligible for moderate-to-severe psoriasis clinical trials
    Wu, J.
    Araujo, A.
    Nordstrom, B.
    Goldblum, O.
    Solotkin, K.
    Lin, C. -Y.
    Johnston, J.
    Kistler, K.
    Fraeman, K.
    Malatestinic, W.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 84 - 84
12345